Barrington lowered the firm’s price target on Opko Health (OPK) to $1.50 from $2.25 and keeps an Outperform rating on the shares. The company reported a better than expected Q4 report, but the way in which it achieved it is concerning, the analyst tells investors in a research note. The firm says “other revenue largely saved the quarter, but this level of performance is not sustainable.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPK:
